首页> 外国专利> LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS.

LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS.

机译:拉喹莫德用于治疗具有高度残疾状态的缓解型多发性硬化症(RRMS)的患者。

摘要

This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.
机译:本发明提供一种根据Kurtzke扩展残疾状况量表(EDSS)治疗或减少诊断为患有复发-缓解多发性硬化症(RRMS)且基线残疾评分高的人类患者的门诊恶化的方法,包括定期仅对诊断为RRMS且基线残疾评分较高的患者给药一定量的拉喹莫德,可有效治疗该患者或减少非卧床恶化。本发明进一步提供了包含有效量的拉喹莫德的药物组合物和包装,所述药物用于治疗被诊断患有RRMS的人类患者,并且根据EDSS具有高的基线残疾评分。

著录项

  • 公开/公告号MX2016013944A

    专利类型

  • 公开/公告日2017-01-09

    原文格式PDF

  • 申请/专利权人 TEVA PHARMACEUTICAL INDUSTRIES LTD.;

    申请/专利号MX20160013944

  • 发明设计人 VOLKER KNAPPERTZ;

    申请日2015-04-28

  • 分类号A61K31/765;A61K47;C07D215;

  • 国家 MX

  • 入库时间 2022-08-21 13:37:42

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号